<DOC>
	<DOCNO>NCT02241187</DOCNO>
	<brief_summary>This study several purpose . DCE-MRI use image tumor . Safety cetuximab give surgery study . Cetuximab delivery tumor study . In Stage 2 study , safety cetuximab PEGPH20 give surgery study . Also , effect PEGPH20 tumor study .</brief_summary>
	<brief_title>Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must histologically cytologically confirm PDAC . Pathologic confirmation mandate initiation protocol specify imaging study drug administration . It recognize patient , histologic cytologic confirmation cancer may obtain follow study enrollment . Patient volunteer DW DCEMRI sequence parameter optimization image portion study eligible pancreatic lesion , histologic cytologic confirmation pathology require patient volunteer group . Radiographically resectable PDAC adjudicate MSKCC surgical oncologist without evidence distant metastasis CT laparoscopy , perform discretion surgeon . Age &gt; 18 year . ECOG Performance Score 0 2 . Absolute neutrophil count &gt; 1,500 cells/mm3 Platelet count &gt; 100,000 cells/mm3 . Adequate renal function evidence serum creatinine &lt; 1.6 mg/dL . INR &lt; 1.5 , unless patient therapeutic anticoagulation therapeutic INR acceptable . Anticoagulation low molecular weight heparin warfarin , medically indicate , permit . Patient volunteer DW DCEMRI sequence parameter optimization portion study exempt criterion 2 , 5 , 6 8 . Women childbearing potential must negative pregnancy test prior administration protocol specify intervention . Ability understand inform consent sign write informed consent prior initiation protocol therapy . Patients histology adenocarcinoma , e.g. , neuroendocrine cancer acinar cancer , ineligible . No prior therapy pancreas cancer allow . Patients metastatic locally unresectable PDAC ( resectability define MSKCC pancreatic surgeon outline Active infection , exception resolve cholangitis , preclude enrollment study . Preoperative intervention initiate acute cholangitis resolve . Patients know hypersensitivity component PEGPH20 cetuximab . For patient choose undergo MRI imaging , hypersensitivity MRI IV contrast medium suitable premedication . Patients receive concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment ( investigational therapy define treatment currently regulatory authority approve indication ) . Patients history venous arterial thromboembolic event include pulmonary embolism , deep venous thrombosis stroke . Patients pregnant lactate For patient choose undergo MRI imaging patient ineligible MRI contrast base Radiology Department screen . Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , follow procedure . Patient volunteer DW DCEMRI sequence parameter optimization portion exempt criterion 12 , 13 , 14 , 15 , 16 18 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PEGPH20</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>14-039</keyword>
</DOC>